Last reviewed · How we verify
23-valent polysaccharide vaccine
23-valent polysaccharide vaccine is a Biologic drug developed by Centers for Disease Control and Prevention. It is currently in Phase 1 development.
At a glance
| Generic name | 23-valent polysaccharide vaccine |
|---|---|
| Sponsor | Centers for Disease Control and Prevention |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Injection site pain
- Injection site pain (PAIN)
- Fatigue
- Headache
- Myalgia (MUSCLE PAIN)
- Fatigue (FATIGUE)
- Myalgia
- Headache (HEADACHE)
- Injection site swelling
- Injection site erythema
- Pain (Any)
- Pain (Mild)
Key clinical trials
- A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013) (PHASE3)
- Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS (PHASE3)
- Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008) (PHASE3)
- Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10) (PHASE3)
- Phase I/II Clinical Trial of Diphtheria-Tetanus-Pertussis (Reduced Dose) Vaccine (PHASE1, PHASE2)
- Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial (PHASE2)
- Vaccine Responses in Patients With B Cell Malignancies (PHASE4)
- Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 23-valent polysaccharide vaccine CI brief — competitive landscape report
- 23-valent polysaccharide vaccine updates RSS · CI watch RSS
- Centers for Disease Control and Prevention portfolio CI
Frequently asked questions about 23-valent polysaccharide vaccine
What is 23-valent polysaccharide vaccine?
23-valent polysaccharide vaccine is a Biologic drug developed by Centers for Disease Control and Prevention.
Who makes 23-valent polysaccharide vaccine?
23-valent polysaccharide vaccine is developed by Centers for Disease Control and Prevention (see full Centers for Disease Control and Prevention pipeline at /company/centers-for-disease-control-and-prevention).
What development phase is 23-valent polysaccharide vaccine in?
23-valent polysaccharide vaccine is in Phase 1.
What are the side effects of 23-valent polysaccharide vaccine?
Common side effects of 23-valent polysaccharide vaccine include Injection site pain, Injection site pain (PAIN), Fatigue, Headache, Myalgia (MUSCLE PAIN), Fatigue (FATIGUE).